PHASE II TRIAL OF PROLONGED, LOW-DOSE, ORAL VP-16 IN AIDS-RELATED KAPOSI'S SARCOMA (KS) (MEETING ABSTRACT) NLM AIDSLINE Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


PHASE II TRIAL OF PROLONGED, LOW-DOSE, ORAL VP-16 IN AIDS-RELATED KAPOSI'S SARCOMA (KS) (MEETING ABSTRACT)

Proc Annu Meet Am Soc Clin Oncol; 11:A13 1992. Unique Identifier : AIDSLINE ICDB/92680744
Bufill JA; Grace WR; Astrow AB; Oncology Section, Dept. of Medicine, St. Vincent's Hosp., New; York, NY 10011

Abstract: Fourteen homosexual men with KS were given 50 mg/day VP-16 po for 21 consecutive days q 28-35 days. Eight patients (pts) had received prior treatment with either interferon (6) or chemotherapy (2), and most pts had experienced an opportunistic infection prior to entry. Their mean absolute CD4 count was 39 cells/mm3 (range 10-119 cells/mm3). All pts completed at least 1 cycle; 8 pts completed 3 or more cycles. No growth factors were administered during or after VP-16 therapy. There were no complete responses. Partial responses occurred in 3 pts (21%). Among pts classified as nonresponders, minor responses were seen in 5 (36%), suggesting some biological effect of the therapy. Predominant toxicities included leukopenia, anemia, infections, alopecia (9 pts), diarrhea (5) and nausea (3). Treatment-related infections included thrush (4 pts), herpes virus infections (4), PCP (2), sepsis (2) and bacterial pneumonia (1). These results, observed in pts with advanced AIDS, suggest that further study of oral VP-16 schedules is warranted, and that routine prophylaxis for thrush and herpes may be indicated.
Keywords: Acquired Immunodeficiency Syndrome/*COMPLICATIONS/IMMUNOLOGY Administration, Oral Antigens, CD4/ANALYSIS Biological Markers Drug Administration Schedule Drug Evaluation Etoposide/ADMINISTRATION & DOSAGE/*TOXICITY/*THERAPEUTIC USE Human Sarcoma, Kaposi's/*DRUG THERAPY/*ETIOLOGY/IMMUNOLOGY CLINICAL TRIAL ABSTRACT

KWDacquiredimmunodeficiencysyndrome/KWDcomplications/immunologyadministration,oralantigens,cd4/analysisbiologicalmarkersdrugadministrationscheduledrugevaluationetoposide/administration&dosage/KWDtoxicity/KWDtherapeuticusehumansarcoma,kaposi's/KWDdrugtherapy/KWDetiology/immunologyclinicaltrialabstract
921130
M92B0896

Copyright © 1992 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .